|
1
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
3
|
Alizadeh AM, Shiri S and Farsinejad S:
Metastasis review: From bench to bedside. Tumour Biol.
35:8483–8523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel LR, Camacho DF, Shiozawa Y, Pienta
KJ and Taichman RS: Mechanisms of cancer cell metastasis to the
bone: A multistep process. Future Oncol. 7:1285–1297. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guan X: Cancer metastases: Challenges and
opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vasaturo F, Solai F, Malacrino C, Nardo T,
Vincenzi B, Modesti M and Scarpa S: Plasma levels of matrix
metalloproteinases 2 and 9 correlate with histological grade in
breast cancer patients. Oncol Lett. 5:316–320. 2013. View Article : Google Scholar
|
|
7
|
Deryugina EI and Quigley JP: Tumor
angiogenesis: MMP-mediated induction of intravasation- and
metastasis-sustaining neovasculature. Matrix Biol. 44–46:94–112.
2015. View Article : Google Scholar
|
|
8
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wigerup C, Påhlman S and Bexell D:
Therapeutic targeting of hypoxia and hypoxia-inducible factors in
cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoo MY, Oh KS, Lee JW, Seo HW, Yon GH,
Kwon DY, Kim YS, Ryu SY and Lee BH: Vasorelaxant effect of
stilbenes from rhizome extract of rhubarb (Rheum undulatum) on the
contractility of rat aorta. Phytother Res. 21:186–189. 2007.
View Article : Google Scholar
|
|
13
|
Moon MK, Kang DG, Lee JK, Kim JS and Lee
HS: Vasodilatory and anti-inflammatory effects of the aqueous
extract of rhubarb via a NO-cGMP pathway. Life Sci. 78:1550–1557.
2006. View Article : Google Scholar
|
|
14
|
Matsuda H, Tewtrakul S, Morikawa T and
Yoshikawa M: Anti-allergic activity of stilbenes from Korean
rhubarb (Rheum undulatum L.): Structure requirements for inhibition
of antigen-induced degranulation and their effects on the release
of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem.
12:4871–4876. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song JH, Yang TC, Chang KW, Han SK, Yi HK
and Jeon JG: In vitro anti-cariogenic activity of dichloromethane
fraction from Rheum undulatum L. root. Arch Pharm Res. 29:490–496.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuda H, Morikawa T, Toguchida I, Park
JY, Harima S and Yoshikawa M: Antioxidant constituents from
rhubarb: Structural requirements of stilbenes for the activity and
structures of two new anthraquinone glucosides. Bioorg Med Chem.
9:41–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ko SK, Lee SM and Whang WK: Anti-platelet
aggregation activity of stilbene derivatives from Rheum
undulatum. Arch Pharm Res. 22:401–403. 1999.
|
|
18
|
Tao L, Cao J, Wei W, Xie H, Zhang M and
Zhang C: Protective role of rhapontin in experimental pulmonary
fibrosis in vitro and in vivo. Int Immunopharmacol. 47:38–46. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei W, Wang L, Zhou K, Xie H, Zhang M and
Zhang C: Rhapontin ameliorates colonic epithelial dysfunction in
experimental colitis through SIRT1 signaling. Int Immunopharmacol.
42:185–194. 2017. View Article : Google Scholar
|
|
20
|
Chen J, Ma M, Lu Y, Wang L, Wu C and Duan
H: Rhaponticin from rhubarb rhizomes alleviates liver steatosis and
improves blood glucose and lipid profiles in KK/Ay diabetic mice.
Planta Med. 75:472–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim A, Im M, Yim NH, Jung YP and Ma JY:
Aqueous extract of Bambusae Caulis in Taeniam inhibits PMA-induced
tumor cell invasion and pulmonary metastasis: Suppression of NF-κB
activation through ROS signaling. PLoS One. 8:e780612013.
View Article : Google Scholar
|
|
22
|
Kim A, Im M, Gu MJ and Ma JY: Ethanol
extract of Lophatheri Herba exhibits anti-cancer activity in human
cancer cells by suppression of metastatic and angiogenic potential.
Sci Rep. 6:362772016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta MK and Qin RY: Mechanism and its
regulation of tumor-induced angiogenesis. World J Gastroenterol.
9:1144–1155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vaupel P: The role of hypoxia-induced
factors in tumor progression. Oncologist. 9(Suppl 5): 10–17. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shang Y, Cai X and Fan D: Roles of
epithelial-mesenchymal transition in cancer drug resistance. Curr
Cancer Drug Targets. 13:915–929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garg M: Epithelial-mesenchymal transition
- activating transcription factors - multifunctional regulators in
cancer. World J Stem Cells. 5:188–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weinberg RA: Oncogenes, antioncogenes, and
the molecular bases of multistep carcinogenesis. Cancer Res.
49:3713–3721. 1989.PubMed/NCBI
|
|
29
|
Colotta F, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mbeunkui F and Johann DJ Jr: Cancer and
the tumor micro-environment: A review of an essential relationship.
Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar
|
|
31
|
Finger EC and Giaccia AJ: Hypoxia,
inflammation, and the tumor microenvironment in metastatic disease.
Cancer Metastasis Rev. 29:285–293. 2010. View Article : Google Scholar
|
|
32
|
Li H, Fan X and Houghton J: Tumor
microenvironment: The role of the tumor stroma in cancer. J Cell
Biochem. 101:805–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cairns R, Papandreou I and Denko N:
Overcoming physiologic barriers to cancer treatment by molecularly
targeting the tumor microenvironment. Mol Cancer Res. 4:61–70.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Joyce JA: Therapeutic targeting of the
tumor microenvironment. Cancer Cell. 7:513–520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang C and Werb Z: The many faces of
metalloproteases: Cell growth, invasion, angiogenesis and
metastasis. Trends Cell Biol. 11:S37–S43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rak JW, St Croix BD and Kerbel RS:
Consequences of angiogenesis for tumor progression, metastasis and
cancer therapy. Anticancer Drugs. 6:3–18. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Semenza GL: HIF-1 and tumor progression:
Pathophysiology and therapeutics. Trends Mol Med. 8(Suppl):
S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeong W, Rapisarda A, Park SR, Kinders RJ,
Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH,
et al: Pilot trial of EZN-2968, an antisense oligonucleotide
inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients
with refractory solid tumors. Cancer Chemother Pharmacol.
73:343–348. 2014. View Article : Google Scholar
|
|
41
|
Patnaik A, Chiorean EG, Tolcher A,
Papadopoulos K, Beeram M, Kee D, Waddell M, Gilles E and Buchbinder
A: EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1α)
messenger ribonucleic acid (mRNA) antagonist: Results of a phase I,
pharmacokinetic (PK), dose escalation study of daily administration
in patients (pts) with advanced malignancies. J Clin Oncol.
27:25642009.
|
|
42
|
Son SH, Kim MJ, Chung WY, Son JA, Kim YS,
Kim YC, Kang SS, Lee SK and Park KK: Decursin and decursinol
inhibit VEGF-induced angiogenesis by blocking the activation of
extracellular signal-regulated kinase and c-Jun N-terminal kinase.
Cancer Lett. 280:86–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoysungnoen P, Wirachwong P, Bhattarakosol
P, Niimi H and Patumraj S: Effects of curcumin on tumor
angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular
carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc.
34:109–115. 2006.PubMed/NCBI
|
|
44
|
Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL,
Cheng HL, Liu HS, Cheng HL, Hsu PY and Chow NH: The novel targets
for anti-angiogenesis of genistein on human cancer cells. Biochem
Pharmacol. 69:307–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jo SP, Kim JK and Lim YH:
Antihyperlipidemic effects of rhapontin and rhapontigenin from
rheum undulatum in rats fed a high-cholesterol diet. Planta Med.
80:1067–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun Y and Zhao Y: Enhanced
pharmacokinetics and anti-tumor efficacy of PEGylated liposomal
rhaponticin and plasma protein binding ability of rhaponticin. J
Nanosci Nanotechnol. 12:7677–7684. 2012. View Article : Google Scholar
|
|
47
|
Yeh YH, Wang SW, Yeh YC, Hsiao HF and Li
TK: Rhapontigenin inhibits TGF-β-mediated epithelial-mesenchymal
transition via the PI3K/AKT/mTOR pathway and is not associated with
HIF-1α degradation. Oncol Rep. 35:2887–2895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JS, Kang CG, Kim SH and Lee EO:
Rhapontigenin suppresses cell migration and invasion by inhibiting
the PI3K-dependent Rac1 signaling pathway in MDA-MB-231 human
breast cancer cells. J Nat Prod. 77:1135–1139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jung DB, Lee HJ, Jeong SJ, Lee HJ, Lee EO,
Kim YC, Ahn KS, Chen CY and Kim SH: Rhapontigenin inhibited hypoxia
inducible factor 1 alpha accumulation and angiogenesis in hypoxic
PC-3 prostate cancer cells. Biol Pharm Bull. 34:850–855. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Martin TA and Jiang WG: Loss of tight
junction barrier function and its role in cancer metastasis.
Biochim Biophys Acta. 1788:872–891. 2009. View Article : Google Scholar
|
|
51
|
Morohashi S, Kusumi T, Sato F, Odagiri H,
Chiba H, Yoshihara S, Hakamada K, Sasaki M and Kijima H: Decreased
expression of claudin-1 correlates with recurrence status in breast
cancer. Int J Mol Med. 20:139–143. 2007.PubMed/NCBI
|
|
52
|
Dhawan P, Singh AB, Deane NG, No Y, Shiou
SR, Schmidt C, Neff J, Washington MK and Beauchamp RD: Claudin-1
regulates cellular transformation and metastatic behavior in colon
cancer. J Clin Invest. 115:1765–1776. 2005. View Article : Google Scholar : PubMed/NCBI
|
